LINCOLN

Lincoln Pharmaceuticals Share Price

₹616.00 -7.45 (-1.19%)

21 Nov, 2024 14:04

SIP TrendupStart SIP in LINCOLN

Start SIP

Performance

  • Low
  • ₹612
  • High
  • ₹625
  • 52 Week Low
  • ₹535
  • 52 Week High
  • ₹812
  • Open Price₹625
  • Previous Close₹623
  • Volume23,018

Investment Returns

  • Over 1 Month -7.01%
  • Over 3 Month -11.92%
  • Over 6 Month + 6.92%
  • Over 1 Year + 2.37%
SIP Lightning

Smart Investing Starts Here Start SIP with Lincoln Pharmaceuticals for Steady Growth!

Invest Now

Lincoln Pharmaceuticals Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 12.8
  • PEG Ratio
  • 0.7
  • Market Cap Cr
  • 1,234
  • P/B Ratio
  • 2.1
  • Average True Range
  • 23.4
  • EPS
  • 48.25
  • Dividend Yield
  • 0.3
  • MACD Signal
  • -9.45
  • RSI
  • 35.62
  • MFI
  • 24.75

Lincoln Pharmaceuticals Financials

Lincoln Pharmaceuticals Technicals

EMA & SMA

Current Price
₹616.00
-7.45 (-1.19%)
pointer
  • stock-down_img
  • Bullish Moving Average 0
  • stock-up_img
  • Bearish Moving Average 16
  • 20 Day
  • ₹653.79
  • 50 Day
  • ₹669.36
  • 100 Day
  • ₹666.47
  • 200 Day
  • ₹640.58

Resistance and Support

621.02 Pivot Speed
  • R3 649.68
  • R2 639.32
  • R1 631.38
  • S1 613.08
  • S2 602.72
  • S3 594.78

What's your outlook on Lincoln Pharmaceuticals?

You can only vote for once

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Lincoln Pharmaceuticals manufactures pharmaceutical formulations across various therapeutic segments, including antibiotics, anti-malarial, and nutraceuticals. With state-of-the-art production facilities, it serves domestic and international markets, exporting products to over 60 countries globally.

Lincoln Pharmaceuticals has an operating revenue of Rs. 597.44 Cr. on a trailing 12-month basis. An annual revenue growth of 15% is outstanding, Pre-tax margin of 21% is great, ROE of 15% is good. The company is debt free and has a strong balance sheet enabling it to report stable earnings growth across business cycles. The stock from a technical standpoint is trading below to its key moving averages. It needs to take out these levels and stay above it to make any meaningful move. From an O'Neil Methodology perspective, the stock has an EPS Rank of 83 which is a GOOD score indicating consistency in earnings, a RS Rating of 30 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at C- which is evident from recent supply seen, Group Rank of 39 indicates it belongs to a strong industry group of Medical-Diversified and a Master Score of C is fair but needs to improve. Institutional holding has gone up in the last reported quarter is a positive sign. Overall, the stock is lagging behind in some of the technical parameters, but great earnings make it a stock to examine in more detail.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Lincoln Pharmaceuticals Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2024-11-14 Quarterly Results
2024-08-08 Quarterly Results
2024-05-16 Audited Results & Final Dividend
2024-02-08 Quarterly Results
2023-11-02 Quarterly Results

Lincoln Pharmaceuticals F&O

Lincoln Pharmaceuticals Shareholding Pattern

49.78%
0%
5.19%
36.14%
8.89%

About Lincoln Pharmaceuticals

  • NSE Symbol
  • LINCOLN
  • BSE Symbol
  • 531633
  • Managing Director
  • Mr. Mahendra G Patel
  • ISIN
  • INE405C01035

Similar Stocks to Lincoln Pharmaceuticals

Lincoln Pharmaceuticals FAQs

Lincoln Pharmaceuticals share price is ₹616 As on 21 November, 2024 | 13:50

The Market Cap of Lincoln Pharmaceuticals is ₹1233.8 Cr As on 21 November, 2024 | 13:50

The P/E ratio of Lincoln Pharmaceuticals is 12.8 As on 21 November, 2024 | 13:50

The PB ratio of Lincoln Pharmaceuticals is 2.1 As on 21 November, 2024 | 13:50

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23